Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT04288427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04288427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Not applicable
Overall status
Recruiting
Start date
September 25, 2020
Completion date
November 30, 2026
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, lower urinary tract symptoms, prostate disease, prostate hyperplasia, prostate hypertrophy, prostate pain, urinary obstruction, urinary tract disease